Skip to content

The Effect and Safety of the transfusion rating scheme scoring in Emergency operation: a prospective, randomized, single-blind controlled clinical trial

The Effect and Safety of the transfusion rating scheme scoring in Emergency operation: a prospective, randomized, single-blind controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004135
Enrollment
Unknown
Registered
2014-01-14
Start date
2014-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergency surgery

Interventions

transfusion rating scheme group :Using the transfusion rating scheme to guide the perioperative blood transfusion

Sponsors

Anesthesia department of the affiliated hospital of zunyi Medical college
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with preoperative Hb less than 10 g/dL, or those with intraoperative Hb may be lower than 10 g/dL (Reference formula: preoperative Hb (g/dL) - [estimated blood loss (ml)/400] <10 g/dL); 2. Patients aged not less than 14 years old; 3. Patients with the permanent elevation less than 2500 meters; 4. ASA classification: Level I~IV; 5. Patients underwent emergency surgeries.

Exclusion criteria

Exclusion criteria: 1. Patients who were likely to appear excessive life-threatening hemorrhage out of control; 2. Patients with blood system diseases, such as aplastic anemia, autoimmune hemolytic anemia, hereditary spherocytosis, thalassemia, paroxysmal nocturnal hemoglobinuria, abnormal hemoglobinopathy, and hemoglobins disability of oxygen carrying (such as methemoglobinemia, etc.); 3. Patients with multiple tumors or/and tumor metastasis; 4. Patients with clear histories of preoperative coronary heart disease; 5. Patients in Neurosurgery and Obstetrics; 6. Patients must be given high hemodilution; 7. Patients had taken other drugs or been involved in other clinical trials within three months prior to the present study; 8. Patients appeared intraoperative deterioration and uncontrollable surgical bleeding.

Design outcomes

Primary

MeasureTime frame
RBC usage amount;mortality rate;complication;

Secondary

MeasureTime frame
Postoperative hemoglobin trends;APACHE_IIScore changes;wound healing;Hospital Stay;

Countries

China

Contacts

Public ContactZhaoqiong ZHU

Affiliated hospital of Zunyi Medical College

ganzhuzhaoqiong@sina.com+86 13035529980

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026